Manfred Ballmann M.D.

Professor

CFRD is the most frequent co-morbidity in CF. The guidelines offers only one treatment option. This option is sc insulin. Nevertheless around 25% of all CFRD patients are not treated with insulin. We review recent data about oral CFRD treatment and shoe real life data from the German CF registry to define a basis for discussion about other treatment options beside insulin.

Appearances